Targeted therapy for triple-negative breast cancer
Targeted therapies, a type of systemic cancer treatment, work by targeting features, called biomarkers, that are needed for cancer cells to survive and grow. Until recently, chemotherapy was the only systemic treatment option for triple-negative breast cancer, and it continues to be the most effective treatment for many people.
This is because triple-negative breast cancers are not fueled by estrogen or progesterone and do not have receptors for the HER2 protein, targets that guided some of the first breast cancer targeted therapies. But new treatments have become available that target biomarkers found in some triple-negative breast cancers.
In this section, you’ll learn more about the different classes of targeted therapies for triple-negative breast cancer, the biomarkers that tell us who may benefit from them, and how they work.